Skip to main content
Retour
YDES logo

YD Bio Limited Ordinary Shares

Qualité des données : 100%
YDES
NASDAQ Healthcare Biotechnology
7,73 €
▲ 1,24 € (19,11%)
Cap. Boursière : 545,13M
Fourchette du Jour
6,58 € 8,77 €
Fourchette 52 Semaines
5,30 € 25,00 €
Volume
138 671
Moyenne 50J / 200J
9,76 € / 12,68 €
Clôture Précédente
6,49 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -386,2 0,4
P/B 82,7 2,9
ROE % -42,7 3,9
Net Margin % -276,6 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Points Clés

Earnings declined -10509,73% over the past year
Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -4,75M
PEG of 0,00 suggests growth is underpriced
Capital intensive — 570,38% of revenue goes to capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)45,76%
Earnings (1Y)-10509,73%
FCF Growth (3Y)N/A

Qualité

Return on Equity
-42,69%
ROIC-16,58%
Net Margin-276,58%
Op. Margin-286,45%

Sécurité

Debt / Equity
0,00
Current Ratio13,18
Interest Coverage-1893,69

Valorisation

P/E Ratio
-386,19
P/B Ratio82,72
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 45,76% Revenue Growth (3Y) N/A
Earnings Growth (1Y) -10509,73% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 510 360,0 Net Income (TTM) -1,41M
ROE -42,69% ROA -20,56%
Gross Margin 30,44% Operating Margin -286,45%
Net Margin -276,58% Free Cash Flow (TTM) -4,75M
ROIC -16,58% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 13,18
Interest Coverage -1893,69 Dividend Yield 0,00%
Valuation
P/E Ratio -386,19 P/B Ratio 82,72
P/S Ratio 1068,13 PEG Ratio 0,00
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 545,13M Enterprise Value 542,02M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 510 360,0 350 131,0 0,0 0,0 0,0
Net Income -1,41M 13 560,0 3,79M 8,70M -2,54M
EPS (Diluted) -0,56 0,00 0,41 0,59 -0,17
Gross Profit 155 356,0 153 445,0 0,0 0,0 0,0
Operating Income -1,46M -9 847,0 -2,32M -1,72M -344 223,0

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 6,86M 321 212,0 17,93M 118,06M 117,59M
Total Liabilities 273 980,0 298 218,0 6,74M 9,11M 17,81M
Shareholders' Equity 6,59M 22 994,0 11,20M 108,96M 99,78M
Total Debt 22 555,0 47 576,0 0,0 0,0 0,0
Cash & Equivalents 3,13M 87 098,0 14 129,0 5 403,0 693 818,0
Current Assets 3,47M 271 724,0 202 705,0 129 560,0 830 767,0
Current Liabilities 263 060,0 298 218,0 5,55M 2,00M 302 219,0